อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - valsartan - tablets - valsartan 160 mg - valsartan - for treatment of hypertension. valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - valsartan - tablets - valsartan 80 mg - valsartan - for treatment of hypertension.valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - risperidone - coated tablets - risperidone 1 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - risperidone - coated tablets - risperidone 2 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - risperidone - coated tablets - risperidone 3 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - risperidone - coated tablets - risperidone 4 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - risperidone - solution - risperidone 1 mg/ml - risperidone - rispond is indicated for the management of schizophrania and manifestation of psychotic disorders. the antipsychotic efficacy of rispond was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. rispond is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. rispond is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. rispond is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distractibility or poor judgment including disruptibe or aggressive behaviors.

อิสราเอล - อังกฤษ - Ministry of Health

rafa laboratories ltd - bilastine - tablets - bilastine 20 mg - bilastine - bilaxten is indicated for the symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticariai in adults and adolescents (12 years of age and over).

อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 100 mg - losartan - hypertension: lotan 100 is indicated for the treatment of hypertension. heart failure:lotan 100 is indicated for the treatment of heart failure, when treatment with an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to lotan 100 is not recommended. renal protection in type-2 diabetic patients with proteinuria: lotan 100 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. lotan 100 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of lotan 100 on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

อิสราเอล - อังกฤษ - Ministry of Health

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 12.5 mg - losartan - heart failure: lotan 12.5 is indicated for the treatment of heart failure, when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to lotan 12.5 mg is not recommended